1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Market Spotlight: Benign Prostatic Hyperplasia

Market Spotlight: Benign Prostatic Hyperplasia

  • April 2018
  • 37 pages
  • ID: 5336372
  • Format: PDF
  • Datamonitor Healthcare


Table of Contents

This Market Spotlight report covers the Benign Prostatic Hyperplasia market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways 
Datamonitor Healthcare estimates that in 2016, there were 595.2 million prevalent cases of benign prostatic hyperplasia among males aged 40 years and older worldwide, and forecasts that number to increase to 728.7 million prevalent cases by 2025. 

Asia is estimated to have had the largest number of prevalent cases in 2016, and Oceania is estimated to have had the smallest number (354.2 million and 3.9 million cases, respectively). 

Approved drugs in the benign prostatic hyperplasia space target phosphodiesterase 5, steroid 5a-reductase, alpha 1 adrenergic receptor, and muscarinic acetylcholine receptor. All marketed drugs for benign prostatic hyperplasia are administered via the oral route. 

The majority of industry-sponsored drugs in active clinical development for benign prostatic hyperplasia are in Phase II. Therapies in development for benign prostatic hyperplasia focus on a wide variety of targets. These therapies are administered via the rectal, percutaneous catheter/injection, intratumoral, intravenous, and oral routes. 

High impact upcoming events comprise topline Phase IIb trial results for OPK-88004, and a pre-NDA meeting with the US Food and Drug Administration for Tamsulosin DRS. 

There have been three licensing and asset acquisition deals involving benign prostatic hyperplasia drugs during 2013–18. The $8.2m agreement between Aceto and Par Pharmaceutical in 2014, under which Aceto’s subsidiary, Rising Pharmaceuticals, purchased three ANDAs from Par Pharmaceutical through the acquisition of doxercalciferol, paricalcitol, and dutasteride capsules, was the only deal with a disclosed value. 

The US parent patents of Xatral (formulation), Cialis (product), Proscar (method of use), and Urief (product) are all set to expire during 2018. 

Cialis’s sales ranked highest among drugs available for BPH during 2012–16. The distribution of clinical trials across Phase I–IV indicates that there is an even distribution of trials for benign prostatic hyperplasia, with 52.3% of trials in Phase I–II, and 47.7% in Phase III–IV. 

The US has a substantial lead in the number of benign prostatic hyperplasia clinical trials globally. Germany leads the major EU markets, while South Korea has the top spot in Asia. 

Clinical trial activity in the benign prostatic hyperplasia space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for benign prostatic hyperplasia, with 65 trials. 

GlaxoSmithKline leads industry sponsors with the highest number of clinical trials for benign prostatic hyperplasia, followed by Astellas and Sanofi.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Creatinine Test Market Research Report by Product, by Test, by Application, by End User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 183 pages

Creatinine Test Market Research Report by Product (Consumables and Instruments), by Test (Blood Test and Urine Test), by Application, by End User, by State (California, Florida, and Illinois) - United ...

  • United States
  • In Vitro Diagnostic Reagent
  • Diagnostics
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on